NO20075648L - Vaksinesammensetning - Google Patents

Vaksinesammensetning

Info

Publication number: NO20075648L
Authority: NO; Norway
Prior art keywords: vectors; adenoviruses; hiv; relates; methods
Prior art date: 2005-05-12

Application number

NO20075648A

Other languages

English (en)

Norwegian (no)

Inventor

Peter Franz Ertl

John Philip Tite

Cathrine Ann Van Wely

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2007-11-06

Publication date

2008-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075648(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-11-06 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-02-07 Publication of NO20075648L publication Critical patent/NO20075648L/no

Links

229960005486 vaccine Drugs 0.000 title 1
241000701161 unidentified adenovirus Species 0.000 abstract 4
239000013598 vector Substances 0.000 abstract 4
241000700605 Viruses Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000013603 viral vector Substances 0.000 abstract 2
241001217856 Chimpanzee adenovirus Species 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
241000990167 unclassified Simian adenoviruses Species 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Biochemistry (AREA)
Zoology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20075648A 2005-05-12 2007-11-06 Vaksinesammensetning NO20075648L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68038905P	2005-05-12	2005-05-12
PCT/EP2006/004854 WO2006120034A1 (fr)	2005-05-12	2006-05-10	Composition de vaccin

Publications (1)

Publication Number	Publication Date
NO20075648L true NO20075648L (no)	2008-02-07

Family

ID=36954770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20075648A NO20075648L (no)	2005-05-12	2007-11-06	Vaksinesammensetning

Country Status (20)

Country	Link
US (1)	US20090208515A1 (fr)
EP (1)	EP1880012B1 (fr)
JP (2)	JP5175178B2 (fr)
KR (1)	KR101451620B1 (fr)
CN (2)	CN101384722A (fr)
AR (1)	AR053275A1 (fr)
AU (1)	AU2006245920A1 (fr)
BR (1)	BRPI0608798A2 (fr)
CA (1)	CA2608316A1 (fr)
EA (1)	EA200702190A1 (fr)
ES (1)	ES2546330T3 (fr)
IL (1)	IL186828A (fr)
MA (1)	MA29458B1 (fr)
MX (1)	MX2007014038A (fr)
NO (1)	NO20075648L (fr)
PE (1)	PE20061372A1 (fr)
SG (1)	SG182173A1 (fr)
TW (1)	TW200716750A (fr)
WO (1)	WO2006120034A1 (fr)
ZA (1)	ZA200709518B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA04004876A (es)	2001-11-21	2004-07-30	Univ Pennsylvania	Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
US20090246220A1 (en)	2006-08-28	2009-10-01	Ertl Hildegund C J	Constructs for enhancing immune responses
CN103550764A (zh) *	2007-03-02	2014-02-05	葛兰素史密丝克莱恩生物有限公司	疫苗组合物及其在刺激免疫反应中的用途
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2009073103A2 (fr) *	2007-11-28	2009-06-11	The Trustees Of The University Of Pennsylvania	Adénovirus simiens sadv-28,27,-29,-32,-33, et -35 de la sous-famille b et utilisations de ceux-ci
KR101662574B1 (ko)	2007-11-28	2016-10-05	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
EP2325298B1 (fr)	2008-03-04	2016-10-05	The Trustees Of The University Of Pennsylvania	ADENOVIRUS DE SINGE SAdV-36, -42.1, -42.2, AND -44 ET LEUR UTILISATION
ES2606511T3 (es)	2011-04-06	2017-03-24	Biovaxim Limited	Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
KR102044051B1 (ko)	2012-03-12	2019-11-12	얀센 백신스 앤드 프리벤션 비.브이.	터미널 말단이 변경된 재조합 아데노바이러스의 배치
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
AU2013262626B2 (en)	2012-05-18	2018-11-29	The Trustees Of The University Of Pennsylvania	Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
US9624510B2 (en)	2013-03-01	2017-04-18	The Wistar Institute	Adenoviral vectors comprising partial deletions of E3
SG11201507524TA (en) *	2013-03-14	2015-10-29	Amgen Inc	Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
EP3271729B1 (fr)	2015-03-18	2020-09-23	Janssen Vaccines & Prevention B.V.	Essais pour des systèmes d'expression recombinants
AU2016249798B2 (en)	2015-04-14	2022-05-26	Janssen Vaccines And Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016198621A1 (fr) *	2015-06-12	2016-12-15	Glaxosmithkline Biologicals Sa	Polypeptides et polynucléotides d'adénovirus
WO2017011336A1 (fr)	2015-07-10	2017-01-19	E.&J. Gallo Winery	Système et procédé de distribution d'une boisson
BR112018072865A2 (pt)	2016-05-12	2019-04-30	Janssen Vaccines & Prevention B.V.	promotor bidirecional potente e equilibrado
US11001858B2 (en)	2016-06-20	2021-05-11	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
EP3490610A4 (fr)	2016-08-01	2020-05-20	The Wistar Institute Of Anatomy And Biology	Compositions et procédés de vecteurs adénoviraux à réplication déficiente pour des applications de vaccin
JP6721797B2 (ja)	2017-02-09	2020-07-15	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	異種遺伝子発現のための強力で短いプロモーター

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6083716A (en) *	1996-09-06	2000-07-04	The Trustees Of The University Of Pennsylvania	Chimpanzee adenovirus vectors
JP2004508064A (ja) *	2000-09-15	2004-03-18	メルク　エンド　カムパニー　インコーポレーテッド	コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
US6733993B2 (en) *	2000-09-15	2004-05-11	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002308713B2 (en) *	2001-06-22	2008-05-15	The Trustees Of The University Of Pennsylvania	Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
JP4601956B2 (ja) *	2001-09-20	2010-12-22	グラクソグループリミテッド	Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
GB0225788D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
GB0225786D0 (en) *	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
GB2406336A (en) *	2003-09-24	2005-03-30	Oxxon Pharmaccines Ltd	HIV Pharmaccines
AU2004276559A1 (en) *	2003-09-24	2005-04-07	Oxxon Therapeutics Limited	HIV pharmaccines
GB0417494D0 (en) *	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine

2006
- 2006-05-10 BR BRPI0608798-1A patent/BRPI0608798A2/pt not_active IP Right Cessation
- 2006-05-10 AR ARP060101875A patent/AR053275A1/es unknown
- 2006-05-10 TW TW095116578A patent/TW200716750A/zh unknown
- 2006-05-10 EA EA200702190A patent/EA200702190A1/ru unknown
- 2006-05-10 JP JP2008510517A patent/JP5175178B2/ja not_active Expired - Fee Related
- 2006-05-10 CN CNA2006800162796A patent/CN101384722A/zh active Pending
- 2006-05-10 MX MX2007014038A patent/MX2007014038A/es active IP Right Grant
- 2006-05-10 PE PE2006000493A patent/PE20061372A1/es not_active Application Discontinuation
- 2006-05-10 ES ES06743016.5T patent/ES2546330T3/es not_active Expired - Lifetime
- 2006-05-10 KR KR1020077029093A patent/KR101451620B1/ko not_active Expired - Fee Related
- 2006-05-10 CN CN2013100023418A patent/CN103088060A/zh active Pending
- 2006-05-10 AU AU2006245920A patent/AU2006245920A1/en not_active Abandoned
- 2006-05-10 SG SG2012041687A patent/SG182173A1/en unknown
- 2006-05-10 CA CA002608316A patent/CA2608316A1/fr not_active Abandoned
- 2006-05-10 WO PCT/EP2006/004854 patent/WO2006120034A1/fr not_active Ceased
- 2006-05-10 EP EP06743016.5A patent/EP1880012B1/fr not_active Expired - Lifetime
- 2006-05-10 US US11/913,952 patent/US20090208515A1/en not_active Abandoned
2007
- 2007-10-22 IL IL186828A patent/IL186828A/en not_active IP Right Cessation
- 2007-11-05 ZA ZA2007/09518A patent/ZA200709518B/en unknown
- 2007-11-06 NO NO20075648A patent/NO20075648L/no not_active Application Discontinuation
- 2007-11-20 MA MA30386A patent/MA29458B1/fr unknown
2012
- 2012-08-24 JP JP2012185395A patent/JP2013046613A/ja active Pending

Also Published As

Publication number	Publication date
US20090208515A1 (en)	2009-08-20
MA29458B1 (fr)	2008-05-02
IL186828A (en)	2015-06-30
JP2013046613A (ja)	2013-03-07
TW200716750A (en)	2007-05-01
MX2007014038A (es)	2008-02-11
PE20061372A1 (es)	2007-01-16
JP2008539746A (ja)	2008-11-20
IL186828A0 (en)	2008-02-09
KR20080021659A (ko)	2008-03-07
AR053275A1 (es)	2007-04-25
EP1880012A1 (fr)	2008-01-23
CN103088060A (zh)	2013-05-08
EP1880012B1 (fr)	2015-07-08
WO2006120034A8 (fr)	2007-11-15
BRPI0608798A2 (pt)	2011-03-15
ZA200709518B (en)	2014-01-29
CN101384722A (zh)	2009-03-11
ES2546330T3 (es)	2015-09-22
WO2006120034A1 (fr)	2006-11-16
JP5175178B2 (ja)	2013-04-03
KR101451620B1 (ko)	2014-10-21
AU2006245920A1 (en)	2006-11-16
EA200702190A1 (ru)	2008-04-28
CA2608316A1 (fr)	2006-11-16
SG182173A1 (en)	2012-07-30

Legal Events

Date	Code	Title	Description
2013-12-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
TW200716750A (en)	2007-05-01	Vaccine composition
NO20090194L (no)	2009-03-10	Rekombinant viral vaksine
Capone et al.	2006	A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
Forrester et al.	2008	Recombination in rabbit haemorrhagic disease virus: possible impact on evolution and epidemiology
WO2008014521A3 (fr)	2008-12-24	Vaccins améliorés et leurs procédés d'utilisation
JP2009544333A5 (fr)	2011-09-01
BR112016020688A2 (pt)	2017-10-03	Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2014534202A5 (fr)	2015-12-03
RU2015135890A (ru)	2017-03-27	Композиция вакцины
RU2019144161A (ru)	2021-08-05	Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
WO2006089001A3 (fr)	2007-07-12	Vecteurs lentiviraux et leurs utilisations
ATE494906T1 (de)	2011-01-15	Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
JP2016501015A5 (ja)	2017-07-27	デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
CY1109036T1 (el)	2014-07-02	Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
DK0604566T3 (da)	2000-04-10	Kimærisk og/eller vækstbegrænsede flavivirus
SA518391787B1 (ar)	2022-08-28	تركيبة لعلاج متلازمة كريغلر نجار
WO2011057254A3 (fr)	2011-08-18	Vaccins à base de vecteur adénoviral simien
EA200601043A1 (ru)	2006-10-27	Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
MXPA05005203A (es)	2006-01-27	Vacuna contra vhc.
WO2008115314A3 (fr)	2009-10-15	Vecteur vaccinal flavivirus contre le virus de la grippe
CO6541529A2 (es)	2012-10-16	Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
WO2008048984A3 (fr)	2008-10-23	Procédés et compositions permettant de préparer un vaccin universel contre la grippe
WO2003076591A3 (fr)	2004-03-25	Compositions et procedes destines a produire une reponse immunitaire
NO20045315L (no)	2004-12-03	Ekspresjon av gener i Modifisert Vacciniavirus Ankara ved a bruke kukoppe ATI-promoteren
WO2012042279A3 (fr)	2012-07-26	Compositions immunogènes de vecteur viral